Trial Profile
An Open-Label Treatment Use Protocol for Daratumumab in Subjects With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or Are Double Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Expanded access
- Sponsors Janssen Research & Development
- 19 Aug 2019 According to a Genmab Media Release, data from this trial will be presented at the 17th International Myeloma Workshop, taking place in Boston, Massachusetts from September 12 to 15, 2019.
- 11 Jan 2019 Status changed from active, no longer recruiting to completed.
- 05 Nov 2018 Results published in the Cancer